Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Tesch

Showing results (201-210 of 282) with videos related to

Pageof 29
Sort By:
Diabetologia|May 26, 2009
Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db miceA K H Lim, F Y Ma, D J Nikolic-Paterson, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Myeloid mineralocorticoid receptor activation contributes to progressive kidney diseaseLouis L Huang, David J Nikolic-Paterson, Yingjie Han, et al.
Clinical and Experimental Immunology|September 6, 2000
Up-regulation of the tumour-associated marker CD44V6 in experimental kidney diseaseK Takazoe, R Foti, G H Tesch, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 10, 1996
[Immunotherapy of hemato-oncologic diseases]U Winkler, H Bohlen, V Schirrmacher, et al.
Current Medical Research and Opinion|August 22, 2008
Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia--examination of practice in GermanyT Steinmetz, U Totzke, U Söling, et al.
Leukemia & Lymphoma|May 31, 2023
Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survivalHans Tilman Steinmetz, J Toczek-Thiel, J Lipke, et al.
Leukemia & Lymphoma|March 18, 2000
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphomaA Josting, M Reiser, P D Wickramanayake, et al.
Journal of Cellular and Molecular Medicine|July 13, 2018
ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritisLiv A Amos, Frank Y Ma, Greg H Tesch, et al.
Nephrology (Carlton, Vic.)|October 27, 2004
Macrophage accumulation and renal fibrosis are independent of macrophage migration inhibitory factor in mouse obstructive nephropathyEdwina K Rice, David J Nikolic-Paterson, John R David, et al.
In Vivo (Athens, Greece)|July 1, 1994
Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6G R Krueger, A Guenther, R Knuefermann, et al.
Pageof 29

Showing results (201-210 of 282) with videos related to

Sort By:
Pageof 29
Diabetologia|May 26, 2009
Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db miceA K H Lim, F Y Ma, D J Nikolic-Paterson, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Myeloid mineralocorticoid receptor activation contributes to progressive kidney diseaseLouis L Huang, David J Nikolic-Paterson, Yingjie Han, et al.
Clinical and Experimental Immunology|September 6, 2000
Up-regulation of the tumour-associated marker CD44V6 in experimental kidney diseaseK Takazoe, R Foti, G H Tesch, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 10, 1996
[Immunotherapy of hemato-oncologic diseases]U Winkler, H Bohlen, V Schirrmacher, et al.
Current Medical Research and Opinion|August 22, 2008
Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia--examination of practice in GermanyT Steinmetz, U Totzke, U Söling, et al.
Leukemia & Lymphoma|May 31, 2023
Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survivalHans Tilman Steinmetz, J Toczek-Thiel, J Lipke, et al.
Leukemia & Lymphoma|March 18, 2000
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphomaA Josting, M Reiser, P D Wickramanayake, et al.
Journal of Cellular and Molecular Medicine|July 13, 2018
ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritisLiv A Amos, Frank Y Ma, Greg H Tesch, et al.
Nephrology (Carlton, Vic.)|October 27, 2004
Macrophage accumulation and renal fibrosis are independent of macrophage migration inhibitory factor in mouse obstructive nephropathyEdwina K Rice, David J Nikolic-Paterson, John R David, et al.
In Vivo (Athens, Greece)|July 1, 1994
Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6G R Krueger, A Guenther, R Knuefermann, et al.
Pageof 29